Cullinan Therapeutics
Develops bispecific T-cell engagers for autoimmune disease and cancer through a hub-and-spoke drug-development model.
$21.70
After-hours close+0.02 (+0.09%)
At close$21.68(−4.07%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.85 | — | — |
| Aug 2026 | −$0.80 | −$0.81 | −1.3% |
| May 2026 | −$0.84 | −$0.75 | +10.3% |
| Mar 2026 | −$0.80 | −$0.77 | +3.8% |
| Nov 2025 | −$0.95 | −$0.77 | +18.9% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Jan 2021 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.85 | — | — | $2.0M | — | — |
| Aug 6, 2026 | −$0.80 | −$0.81 | −1.3% | $3.7M | — | — |
| May 7, 2026 | −$0.84 | −$0.75 | +10.3% | $3.7M | — | — |
| Mar 10, 2026 | −$0.80 | −$0.77 | +3.8% | $5.0M | — | — |
| Nov 6, 2025 | −$0.95 | −$0.77 | +18.9% | $5.6M | — | — |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 15, 2024 | ||||||
| Mar 14, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 16, 2022 | ||||||
| Mar 17, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Aug 10, 2021 | ||||||
| May 14, 2021 | ||||||
| Mar 30, 2021 | ||||||
| Jan 6, 2021 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||